Lonza stock advances as investors weigh earnings momentum

Lonza stock is framed by the Swiss group’s 2024 scale: CHF 6.6 billion in sales and CHF 1.1 billion in core EBITDA, with the company reporting a core EBITDA margin of 16.8% for the year. Lonza Group AG (ISIN CH0013841017) also said 2024 sales rose 20.9% and core EBITDA increased 22.0% at constant exchange rates, giving investors a clear reference point for the shares.

Sales up 20.9%

Lonza reported 2024 sales of CHF 6.6 billion, up 20.9% at constant exchange rates, while core EBITDA reached CHF 1.1 billion, up 22.0% at constant exchange rates. The margin of 16.8% shows that the growth was not only top-line driven but also translated into operating leverage.

That combination matters because the group entered 2025 with a larger revenue base and a stronger profitability profile than a year earlier. For equity holders, the comparison is straightforward: a 22.0% core EBITDA increase against 20.9% sales growth points to a business that kept more of each additional franc.

Margin at 16.8%

The 16.8% core EBITDA margin is the key operating number in the latest annual set, because it links scale to efficiency. Lonza’s reported CHF 1.1 billion core EBITDA on CHF 6.6 billion of sales also implies a sizable absolute earnings base for a contract-development and manufacturing group.

In the same 2024 reporting frame, the company’s constant-currency growth rates provide the clearest quantified comparison available: sales rose 20.9% and core EBITDA rose 22.0%. That spread is small, but it still signals that profitability expanded slightly faster than revenue over the year.

CDMO scale matters

Lonza’s contract-development and manufacturing model depends on long customer programs, production capacity, and operating discipline. The 2024 figures show why the market tends to focus on margin quality rather than revenue alone: CHF 6.6 billion of sales and CHF 1.1 billion of core EBITDA leave room for further cash generation if utilization remains high.

The company’s annual disclosures also give investors a cleaner benchmark than a single trading session. With sales up 20.9% and core EBITDA up 22.0% in 2024, the business entered the next phase with growth that was broad enough to matter and profitability that moved in the same direction.

Biologics remain central

Lonza’s most relevant product and service exposure remains biologics and complex manufacturing for biopharma customers, where demand is usually measured by long project cycles rather than consumer-style unit sales. That makes the annual revenue and EBITDA trend more important than product headlines alone.

In practical terms, the 2024 sales figure of CHF 6.6 billion is the broad operating signal, while CHF 1.1 billion in core EBITDA is the profitability anchor. For investors tracking Lonza stock, the pair helps separate business momentum from market noise.

Annual numbers first

Lonza stock is best read through the company’s reported 2024 fundamentals until a new dated market move is evidenced. The latest annual data put sales at CHF 6.6 billion, core EBITDA at CHF 1.1 billion, and the core EBITDA margin at 16.8%.

Those figures are the most usable reference points for the shares here because they are concrete, dated, and internally consistent. The 20.9% sales increase and 22.0% core EBITDA increase at constant exchange rates also provide the clearest year-on-year comparison in the available evidence.